Vaccines are moving beyond traditional infectious disease prevention into broader therapeutic and personalised medicine applications.

According to Visiongain analysis, the global vaccine sales market is estimated at US$76.40 billion in 2026 and is forecast to grow at a 6.3% CAGR to US$141.40 billion by 2036. But the story is no longer just about volume. Growth is increasingly being shaped by mRNA platforms, personalised cancer vaccines, fill-finish capacity and more regionalised manufacturing.

In this article, we examine how vaccines are becoming a broader pharma growth market linking commercial demand, platform innovation, oncology and the capacity to deliver at scale.

Visiongain Top Takeaways

• Vaccines are moving beyond prevention: growth is moving into adult immunisation, preparedness and oncology.
• mRNA is the platform to watch: its value lies in speed, flexibility and repeat-use potential.
• Cancer vaccines raise the stakes: personalised mRNA vaccines could pull vaccines into high-value oncology.
• Capacity is becoming competitive advantage: fill-finish, CDMOs and regional production now matter as much as pipeline strength.
• The winners will execute, not just innovate: growth will favour companies that connect science, scale and market access.

Demand is becoming broader and more durable

Vaccine growth is no longer being shaped by childhood immunisation alone.

Government-funded programmes remain the backbone of the market, turning public-health priorities into recurring procurement. This is particularly important in low- and middle-income countries, where HPV, pneumococcal, rotavirus and other vaccine introductions continue to support long-term volume growth.

The market is also widening. Ageing populations, chronic disease pressure and the shift towards preventive healthcare are increasing the role of adult vaccination. Influenza, pneumococcal disease, shingles, RSV and HPV are now part of a broader lifecycle immunisation model, extending commercial opportunity beyond paediatric schedules and outbreak response.

Infectious disease risk is adding further momentum. Measles, pertussis, respiratory infections and emerging viral threats are keeping vaccination high on public-health agendas. Catch-up campaigns are also becoming more important as healthcare systems work to close immunity gaps.

Visiongain insight: the commercial value of the vaccine market is becoming more balanced. Growth is no longer tied to a single procurement cycle, age group or disease area. Manufacturers with portfolios spanning paediatric, adult, seasonal and outbreak-linked vaccines will be better placed to manage demand volatility and protect long-term revenue.

mRNA is changing the competitive frame

mRNA is moving from pandemic-response technology to a broader vaccine development engine.

Visiongain estimates the global mRNA vaccines market at US$9,669.3 million in 2026, with growth forecast at a 13.6% CAGR to US$34,713.4 million by 2036. That growth reflects a shift in how the technology is used: not only for single products but also as a repeatable platform for multiple disease targets.

Its appeal lies in speed, adaptability and common infrastructure. Advances in sequence design, lipid nanoparticle delivery and self-amplifying mRNA are improving stability, immune response and manufacturing efficiency. Visiongain analysis highlights hundreds of mRNA candidates and ongoing clinical programmes spanning infectious disease, oncology, rare diseases and immune-mediated conditions.

As delivery systems, production processes and regulatory pathways mature, companies can apply the same underlying technology across several programmes. The risks remain real: delivery, durability, safety, cost and scale will continue to shape adoption. But the question for vaccine developers is changing. It is no longer only about which mRNA product reaches the market next; it is about whether the company has the technical base, partners, and production model to keep innovating across indications.

Visiongain insight: mRNA’s strategic value is moving from speed to repeatability. The companies best placed to benefit will be those that can turn platform learning into a pipeline advantage, reusing know-how across targets while reducing development, transfer and scale-up risk.

Cancer vaccines are changing the market story

Oncology is where the vaccine market starts to look different.

mRNA cancer vaccines illustrate how vaccine technologies are expanding beyond prevention into therapeutic oncology applications. Personalised vaccines are designed around tumour-specific neoantigens, with the aim of training the immune system to recognise and attack cancer cells.

The field remains early-stage, but clinical and commercial confidence is increasing. Visiongain estimates the global mRNA cancer vaccine market at US$1,288.1 million in 2026, with a forecast 27.1% CAGR to reach US$14,122.8 million by 2036. That outlook reflects rising investment in precision oncology, stronger clinical validation and the need for scalable personalised manufacturing.

Visiongain’s research highlights Moderna and Merck & Co.’s mRNA-4157/V940 programme, used with Keytruda, as one of the most advanced examples. Reported data showed an approximately 49% reduction in the risk of recurrence or death in high-risk melanoma, supporting continued late-stage development programmes in melanoma and non-small cell lung cancer.

For pharma leaders, the point is not only clinical. If cancer vaccines progress, vaccines become part of the high-value oncology market, not just the public-health market. That changes the commercial model, reimbursement case and partner mix. Outcome-linked pricing may become increasingly important if payers are asked to fund high-cost personalised therapies based on long-term reductions in recurrence.

Personalised cancer vaccines also bring a harder delivery challenge: sequencing, neoantigen selection, rapid design, small-batch production and tight clinical logistics. The market will depend not only on strong trial data, but on whether companies can make individualised production work at scale.

Visiongain insight: mRNA cancer vaccines are likely to test the vaccine industry’s next growth model: one built less around high-volume standardised supply and more around precision manufacturing, oncology partnerships and outcome-based value.

Manufacturing is becoming the constraint

Vaccine growth will depend on more than scientific progress. It will depend on whether companies can make, fill and supply complex products reliably.

Visiongain estimates the global vaccine contract manufacturing market at US$3,947.4 million in 2026, with a forecast 10.9% CAGR to US$ 11,065.6 million by 2036.

As pipelines diversify across subunit, recombinant, viral-vector and mRNA technologies, sponsors need partners that can manage multiple platforms, process transfer, quality systems and commercial scale-up. Fill-finish is also moving higher up the agenda, as delays in aseptic filling can affect launch timelines, procurement commitments and supply reliability.

Regionalisation adds further pressure. Local production and technology transfer can improve supply security, but they also bring regulatory complexity, workforce requirements and higher capital costs. For CMOs, this shifts the role from outsourced capacity provider to execution partner.

Visiongain insight: vaccine competition will not be decided by pipeline strength alone. Manufacturing credibility, especially in fill-finish, tech transfer and multi-platform production, is becoming a commercial advantage in its own right.

The competitive landscape is becoming more ecosystem-led

The vaccine market is no longer shaped only by companies with large commercial portfolios. Growth now depends on vaccine developers, mRNA platform specialists, oncology partners, delivery technology providers and contract manufacturers.

In established vaccines, companies such as GSK, Pfizer, Sanofi, AstraZeneca, CSL Seqirus, Bavarian Nordic, Serum Institute of India and Novavax remain important across adult immunisation, infectious disease, respiratory vaccines and public procurement.

In mRNA and oncology, Moderna, Merck & Co., BioNTech, Arcturus Therapeutics, eTheRNA, Ethris, Strand Therapeutics and Acuitas Therapeutics are helping shape platform development, delivery systems and personalised medicine.

Manufacturing adds another layer, with Lonza, Catalent, FUJIFILM Biotechnologies, WuXi Biologics, Recipharm, Charles River Laboratories, Curia, IDT Biologika and Ajinomoto Bio-Pharma competing around technical depth, regulatory credibility, flexible capacity and regional reach.

Visiongain insight: vaccine growth is becoming less dependent on single-company leadership and more dependent on ecosystem strength. The companies best placed for the next phase will be those that can connect science, manufacturing, market access and partnership execution.

Market outlook: vaccines become a platform market

The vaccine market is entering a more complex growth phase.

Demand remains anchored in immunisation programmes, adult vaccination and outbreak preparedness. But future value is likely to be created across a wider chain: platform technologies, personalised oncology, fill-finish capacity, regional manufacturing and partnership-led commercialisation.

For pharma leaders, investors and business development teams, this changes how the market should be assessed. Sales growth still matters, but it is no longer the only measure of opportunity. The more important question is whether companies can connect innovation with execution.

That means looking at:

• platform technologies that can support multiple indications
• adult and lifecycle immunisation strategies
• personalised oncology applications
• fill-finish and complex manufacturing capacity
• regional supply resilience and technology transfer
• partnerships that combine science, scale and market access

The winners will not necessarily be the companies with the largest vaccine portfolios today. They will be the organisations that can link demand, platform innovation, manufacturing credibility, and commercial reach.

Visiongain insight: vaccines are becoming one of pharma’s most important platform markets. Future advantage is likely to favour companies that can integrate scientific design, clinical validation, manufacturing scale, market access and commercial execution across the full value chain.

Latest Reports

Detailed market forecasts, competitive analysis, and sector insights help R&D, manufacturing, supply chain, and commercial teams make decisions.

• Vaccine Sales Market Report 2026-2036
• mRNA Vaccines Market Report 2026-2036
• mRNA Cancer Vaccine Market Report 2026-2036
• Vaccine Contract Manufacturing Market Report 2026-2036
• Pharmaceutical Contract Manufacturing Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com